UNICREDIT BANK/CALL/ELI LILLY & CO/1100/0.1/14.01.26 | Real-time BOERSE MUENCHEN 12:41:36 23/05/2024 BST | ||
| 6.03 EUR | 0.00% |
|
| Current month | +7.30% | ||
| 1 month | +32.53% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 23/05/24 | 6.03 | 0.00% |
| 22/05/24 | 6.03 | +0.67% |
| 21/05/24 | 5.99 | +14.53% |
| 20/05/24 | 5.23 | +3.77% |
| 17/05/24 | 5.04 | -2.33% |
Real-time BOERSE MUENCHEN
Last update May 23, 2024 at 12:41 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
UniCredit
|
| WKN | HD2FCM |
| ISIN | DE000HD2FCM3 |
| Date issued | 05/02/2024 |
| Strike | 1,100 $ |
| Maturity | 14/01/2026 (601 Days) |
| Parity | 10 : 1 |
| Emission price | 3.38 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 6.31 € |
|---|---|
| Lowest since issue | 3.25 € |
| Spread | 0.39 € |
| Spread % | 6.17% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
802.9
USD
Average target price
850.4
USD
Spread / Average Target
+5.92%
- Stock Market
- Warrants
- Warrant
